Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-012
2022-502116-36-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab + Lenvatinib + TACE with TACE + placebo (2 arms). Primary endpoints: Progression-free survival per RECIST 1.1 and Overall survival. Started Jul 2023; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-502116-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502116-36-00.